Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial

IMPORTANCE: Previous communication has reported significant improvement in overall survival (OS) when using doxorubicin plus sorafenib in the treatment of advanced hepatocellular cancer (HCC). OBJECTIVE: To determine if doxorubicin added to sorafenib therapy improves OS, with stratification for loca...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:JAMA Oncol
Asıl Yazarlar: Abou-Alfa, Ghassan K., Shi, Qian, Knox, Jennifer J., Kaubisch, Andreas, Niedzwiecki, Donna, Posey, James, Tan, Benjamin R., Kavan, Petr, Goel, Rakesh, Lammers, Philip E., Bekaii-Saab, Tanios S., Tam, Vincent C., Rajdev, Lakshmi, Kelley, Robin K., El Dika, Imane, Zemla, Tyler, Potaracke, Ryan I., Balletti, Jennifer, El-Khoueiry, Anthony B., Harding, James J., Suga, Jennifer M., Schwartz, Lawrence H., Goldberg, Richard M., Bertagnolli, Monica M., Meyerhardt, Jeffrey, O’Reilly, Eileen M., Venook, Alan P.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Medical Association 2019
Konular:
Original Investigation
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6735405/
https://ncbi.nlm.nih.gov/pubmed/31486832
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2019.2792
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller